DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, To The Board Of Directors

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 11, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it has appointed Lynda Cranston, BScN, MScN, ICD.D, to its Board of Directors as an independent director. Ms. Cranston serves as Chair of the Company's newly formed Governance and Compensation Committee.

Ms. Cranston is an accomplished health care executive with over 20 years of leadership expertise including noteworthy experience as board chair, president and chief executive officer. She is a seasoned director with a significant background in board governance and has achieved an ICD.D designation as a member with the Institute of Corporate Directors.

"We are pleased to welcome Ms. Cranston to the Company's board," stated Jeffrey Bacha, DelMar's president and CEO. "Her vast understanding of the corporate governance landscape will be instrumental as we continue to take meaningful steps in the execution of the Company's strategy toward the up-listing of our common stock to a national exchange. Given Ms. Cranston's previous board experience and background in the ever-evolving healthcare business environment, we believe her guidance will be invaluable to the Company."

Ms. Cranston was identified by the Canadian Board Diversity Council in 2013 as one of Canada's most board-ready candidates. Her most current governance experience was as a board member of the Michael Smith Foundation for Health Research, as Chair of the Child & Family Research Institute, and Health Shared Services British Columbia. Ms. Cranston was a Governor of the Business Council of British Columbia and has been a director in more than 15 additional organizations, including serving as chair in numerous prior board roles. Ms. Cranston presently serves as Chair of the Canadian national Gastrointestinal Society.

"DelMar is an exciting emerging company and I am impressed with the team's commitment to finding solutions for orphan cancer indications with the advancement of its promising drug candidates," commented Ms. Cranston. "I believe the Company has been positioned for an exciting 2015, and I look forward to working closely with management and the current directors to achieve its near and long-term objectives."

Ms. Cranston's most recent health care industry experience was that of Chief Executive Officer of the Provincial Health Services Authority in British Columbia, where she was responsible for highly specialized services within the province, with a budget of $2.5 billion. Previously she was Chief Executive Officer of Fraser Health in British Columbia, Canadian Blood Services in Ottawa, Ontario, the Children's and Women's Healthcare Centre of British Columbia.

In 2008, the HealthCare Leaders' Association of British Columbia awarded Ms. Cranston the Board Chair Award of Excellence, and in 2007, the Women's Executive Network inducted her into Canada's Most Powerful Women Top 100 Hall of Fame. She is a also a recipient of the YWCA Women of Distinction Award, the 125th Anniversary of the Confederation of Canada Commemorative Medal for community contributions, and the Queen's Golden Jubilee Medal for her contribution to Canada and her community. Ms. Cranston earned her BScN at the University of Ottawa and her MScN at the University of Western Ontario and is a graduate of the Rotman School of Management and the Institute of Corporate Directors Program.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Amato & Partners LLC, Investor Relations [email protected]
follow us on Twitter @delmarpharma or Facebook.com/delmarpharma.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.